Cochrane · systematic review · CD007107
Prophylactic antibiotics or G(M)‐CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy
Skoetz, N, Bohlius, J, Engert, A, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
5
No studies
7
Included studies
NR
No studies 7 · 58.3%Ungraded 0 · 0%Very low 2 · 16.7%Low 3 · 25%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: cancer patients receiving myelotoxic chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All cause mortality | no estimate extracted | NR | No studies |
Infection‐related mortality | no estimate extracted | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life | no estimate extracted | NR | No studies |
Incidence of febrile neutropenia | RR 1.22 [0.53, 2.84] | 1 study · 40 participants | Very low Downgraded: risk of bias, imprecision |
Incidence of severe infections | no estimate extracted | NR | No studies |
Adverse events | no estimate extracted | NR | No studies |
Comparison
Population: cancer patients receiving myelotoxic chemotherapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All cause mortality | no estimate extracted | 1 study · 115 participants | Low Downgraded: imprecision |
Infection‐related mortality | no estimate extracted | NR | No studies |
Quality of life | no estimate extracted | NR | No studies |
Incidence of febrile neutropenia | no estimate extracted | NR | No studies |
Incidence of severe infections (Grade III or IV) | RR 1.55 [0.86, 2.8] | 1 study · 115 participants | Low Downgraded: imprecision |
Adverse events Toxic deaths | RR 1.32 [0.3, 5.69] | 1 study · 115 participants | Low Downgraded: imprecision |